Abstract
Obesity is becoming a major public health problem worldwide. Its prevalence is increasing as well as the burden of diet-related chronic diseases including hypertension, diabetes, cardiovascular disease, stroke, and certain cancers. The link between obesity and chronic diseases is well established. Obese individuals are two to three times more likely to die prematurely than their lean counterparts, primarily due to the association between obesity and type 2 diabetes and CHD. Over the past 20 years, there has been an increase in the scientific interest in the impact of omega-3 and omega- 6 fatty acids on human health. Several epidemiological and experimental studies have been published on the cardiovascular (CV) benefits of omega-3 fatty acids. Fish and fish oil are rich sources of omega- 3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Alpha-linolenic acid (ALA) is an omega-3 fatty acid present in seeds and oils, green leafy vegetables, and nuts and beans. Linoleic acid (LA), an omega-6 fatty acid, is present in grains, meats, and the seeds of most plants. In addition, conjugated linoleic acid (CLA) , a group of positional and geometric isomers of linoleic acid characterized by the presence of conjugated dienes, seems to confer specific cardiovascular benefits. The potential for unsaturated fatty acids to counteract the negative effects of obesity is substantial and deserves further investigation.
Keywords: Polyunsaturated fatty acids, obesity, body composition, conjugated linoleic acid
Current Pharmaceutical Design
Title: Fatty Acids and Obesity
Volume: 15 Issue: 36
Author(s): Bermudez Menendez de la Granda M. and Sinclair A. J.
Affiliation:
Keywords: Polyunsaturated fatty acids, obesity, body composition, conjugated linoleic acid
Abstract: Obesity is becoming a major public health problem worldwide. Its prevalence is increasing as well as the burden of diet-related chronic diseases including hypertension, diabetes, cardiovascular disease, stroke, and certain cancers. The link between obesity and chronic diseases is well established. Obese individuals are two to three times more likely to die prematurely than their lean counterparts, primarily due to the association between obesity and type 2 diabetes and CHD. Over the past 20 years, there has been an increase in the scientific interest in the impact of omega-3 and omega- 6 fatty acids on human health. Several epidemiological and experimental studies have been published on the cardiovascular (CV) benefits of omega-3 fatty acids. Fish and fish oil are rich sources of omega- 3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Alpha-linolenic acid (ALA) is an omega-3 fatty acid present in seeds and oils, green leafy vegetables, and nuts and beans. Linoleic acid (LA), an omega-6 fatty acid, is present in grains, meats, and the seeds of most plants. In addition, conjugated linoleic acid (CLA) , a group of positional and geometric isomers of linoleic acid characterized by the presence of conjugated dienes, seems to confer specific cardiovascular benefits. The potential for unsaturated fatty acids to counteract the negative effects of obesity is substantial and deserves further investigation.
Export Options
About this article
Cite this article as:
M. de la Granda Bermudez Menendez and J. A. Sinclair, Fatty Acids and Obesity, Current Pharmaceutical Design 2009; 15 (36) . https://dx.doi.org/10.2174/138161209789909674
DOI https://dx.doi.org/10.2174/138161209789909674 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Multiomics Investigation of Hypertension and White Matter Hyperintensity as a Source of Vascular Dementia or a Comorbidity to Alzheimer’s Disease
Current Alzheimer Research Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris
Current Drug Safety Connective Tissue Remodeling: Cross-Talk between Endothelins and Matrix Metalloproteinases
Current Vascular Pharmacology Tivozanib: A New Hope for Treating Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Resurgence of H3N2 in India: Is it Life-threatening?
Current Drug Targets Effects of Kallistatin on Oxidative Stress and Inflammation on Renal Ischemia-Reperfusion Injury in Mice
Current Vascular Pharmacology Selective Inhibition of Neuronal Nitric Oxide Synthase by L-Arginine Derivatives
Letters in Drug Design & Discovery Editorial [Hot topic: The Inflammation Paradigm in Cardiovascular Disease (Guest Editor: Guha Krishnaswamy)]
Cardiovascular & Hematological Disorders-Drug Targets Cancer Neovascularization and Proinflammatory Microenvironments
Current Cancer Drug Targets Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Differential Expression of microRNAs in Acute and Chronic Heart Failure
Current Medicinal Chemistry The Cell Engraftment Hypothesis of Cardiac Repair
Current Stem Cell Research & Therapy Recent Patents on Microbial Proteases for the Dairy Industry
Recent Advances in DNA & Gene Sequences (Discontinued) Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOC: Associations with Risk Factors
Current Radiopharmaceuticals Central Blood Pressure in Chronic Kidney Disease: Latest Evidence and Clinical Relevance
Current Hypertension Reviews Vascular Arginase and Hypertension
Current Hypertension Reviews Strategies for Salt Reduction in Foods
Recent Patents on Food, Nutrition & Agriculture The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin
Current Vascular Pharmacology